sb 239063 has been researched along with leukotriene d4 in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adams, JL; Bochnowicz, S; Carpenter, DC; Griswold, DE; Hay, DW; Kotzer, CJ; Lee, JC; Osborn, RR; Thomas, HC; Underwood, DC; Webb, EF | 1 |
1 other study(ies) available for sb 239063 and leukotriene d4
| Article | Year |
|---|---|
SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence.
Topics: Administration, Inhalation; Animals; Apoptosis; Blotting, Western; Bronchoalveolar Lavage Fluid; Bronchoconstriction; Calcium-Calmodulin-Dependent Protein Kinases; Cytokines; Enzyme Inhibitors; Eosinophilia; Guinea Pigs; Humans; Imidazoles; Leukotriene D4; Lipopolysaccharides; Mice; Mice, Inbred BALB C; Mitogen-Activated Protein Kinases; Monocytes; p38 Mitogen-Activated Protein Kinases; Phagocytosis; Plethysmography, Whole Body; Pyrimidines; Respiratory System; Tumor Necrosis Factor-alpha | 2000 |